KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence
Open accessPublished version of a preprint
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) patients eligible for curative surgery undergo unpredictable disease relapse. Even patients with a good pathological response after neoadjuvant treatment (NAT) remain susceptible to recurrent PDAC. Molecular analysis of R0 margins may identify patients with a worse prognosis. The molecular status of mutant KRAS (exon 2, codon 12/13) was analysed retrospectively by digital droplet PCR in tumour areas, venous and resection margins of resected tumours, either undergoing up-front surgery (UFS) or after NAT with a good pathological response. Expectedly, tumour tissues or remnants from patients who underwent NAT presented lower KRAS mutant allele frequencies (MAF) than patients eligible for UFS. Similarly, ypT1 tumour MAFs were greater than the ypT0 tumour remnant MAFs in the NAT group. Mutant KRAS status in margins did not distinguish NAT subgroups. It was not predictive of shorter recurrence-free or overall survival within or between groups. KRAS -double negativity in both venous and resection margins did not identify patients with a better prognosis, regardless of the groups. The cohorts ‘sizes were small due to limited numbers of patients meeting the inclusion criteria, but KRAS -positivity or MAFs in resection and venous margins did not carry prognostic value. Comparison of margins from good versus bad responders receiving NAT may provide better clinical value.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The prevalence of KRAS mutations in pancreatic tumors is striking, with mutations of the KRAS gene being present in 90–95% of pancreatic adenocarcinomas, making it the most frequently mutated gene in this type of cancer [97].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621
Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21388 · Cited by 6,502
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269
EMT and Dissemination Precede Pancreatic Tumor Formation
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136
Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes
McGuigan, A., Kelly, P., Turkington, R. C., Jones, C., Coleman, H. G., & McCain, R. S. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i43.4846 · Cited by 1,908
Gillen, S., Schuster, T., Meyer zum Büschenfelde, C., Friess, H., & Kleeff, J. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000267 · Cited by 1,552
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Buscail, L., Bournet, B., & Cordelier, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0245-4 · Cited by 721
KRAS: feeding pancreatic cancer proliferation
Bryant, K. L., Mancias, J. D., Kimmelman, A. C., & Der, C. J. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.12.004 · Cited by 675
Cited by
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040177 · Cited by 110
Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
Kung, H., & Yu, J. (2023) · MedComm · doi:10.1002/mco2.216 · Cited by 46
Rullier, A., Amintas, S., Marques, M., Bail, B. L., Belleannée, G., Dubus, P. R., Vergara, R., & Bernard, N. (2025) · Pathology · doi:10.1016/j.pathol.2024.12.639 · Cited by 8
Self-citationPancreatic ductal adenocarcinoma: integrating molecular insights for targeted interventions
Nagaraju, G. P., Nellipudi, H. R., Ganji, C., Kuppala, V., Ganji, S. P., Kumari, S., Farran, B., Srilatha, M., Guenter, R. E., & El‐Rayes, B. F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02705-5 · Cited by 9
Zheng, D., Grandgenett, P. M., Zhang, Q., Baine, M. J., Shi, Y., Du, Q., Liang, X., Wong, J., Iqbal, S., Preuss, K., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-62741-5 · Cited by 7
Metadata
- Authors
- Amintas, S., Fernandez, B., Chauvet, A., Chiche, L., Laurent, C., Belleannée, G., Marty, M., Buscail, E., & Dabernat, S.
- Affiliations
- Université de Bordeaux (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Inserm (FR)
- Corresponding author
- Dabernat, Sandrine
- Venue
- Scientific Reports
- Published
- 2022-02-22
- Volume
- 12
- Issue
- 1
- Pages
- 2976-2976
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC8864048
- OpenAlex
- W4220929504
- Cited by
- 17
- References
- 37
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 6 · 2023: 2
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fonds Patrick Brou de Laurière
- Ligue Régionale contre le cancer
- GIRCI-SOHO
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Keywords
- pancreatic ductal adenocarcinoma, KRAS mutation, surgical margins, recurrence, neoadjuvant therapy, pathological response, mutant allele frequency, prognosis, droplet digital PCR
- MeSH terms
- Margins of Excision, Aged, Female, Humans, Male, Middle Aged, Mutation, Neoplasm Recurrence, Local, Pancreatic Neoplasms, Prognosis, Proto-Oncogene Proteins p21(ras), Neoadjuvant Therapy, Carcinoma, Pancreatic Ductal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence. https://app.cochat.ai/papers/10.1038/s41598-022-07004-x
- The paper
- Amintas, S., Fernandez, B., Chauvet, A., Chiche, L., Laurent, C., Belleannée, G., Marty, M., Buscail, E., & Dabernat, S. (2022). KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence. Scientific Reports. https://doi.org/10.1038/s41598-022-07004-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.